Venlo, The Netherlands, April 18, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the first quarter 2023.
Press release date / time: Wednesday, May 3, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, May 4, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.
Three options for joining the conference call
- Register for call back connection - Click here: Connect me
Service available 15 minutes before call start
- Dial-in by phone
U.S.: +1 929 477 0402
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2490
Conference ID: 5702254
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
- Access the audio webcast - Click here: Access Webcast
A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1596346&tp_key=edbc0e49e6
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
